Twenty-nine patients with advanced non-small cell lung cancer initiated on immune therapy with anti-PD1/PDL-1 therapy either alone or in combination with platinum-based chemotherapy were enrolled in this prospective trial. The gene discussed is RPL17; the disease is non-small cell lung carcinoma.